and is given after the first series of pneumococcal vaccines. PCV15 and PCV20 are newer vaccines – they were first licensed for adults in 2021 and were approved for kids in 2023. They replaced ...

You have a good eye. This past fall, the Centers for Disease Control and Prevention changed the recommended age for getting the vaccine for pneumococcal pneumonia from those 65 and older to those ...

Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data -- -- Company Expects to ...

Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD. Just-reported ...

The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive ...

Vaxcyte (PCVX) announced that the first study participants have been dosed in the second and final stage of the ongoing Phase 2 study of VAX-31 ...

Vaxcyte has advanced to the Phase II trial’s second and final stage (Stage 2) assessing its 31-valent pneumococcal conjugate vaccine (PCV ... dose immunisation series in mid-2026.

A clear endorsement from their health care provider and being supplied with information about recommended vaccines before ...

Beginning at a very young age, babies are vaccinated to prevent more than a dozen serious diseases, and failure to vaccinate ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Beginning at a very young age, babies are vaccinated to prevent more than a dozen serious diseases, and failure to vaccinate ...

Dr. Matthew Simmons, UPMC Western Maryland vice president of medical staff affairs, said vaccines provide the "single most powerful intervention" that have saved lives. He recently discussed the ...